Picture of bioXXmed AG logo

T5O0 bioXXmed AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Cytotools: results from phase II/III trial for treatment of leg ulcers with DermaPro

May 23 (Reuters) - Cytotools AG  T5OG.DE : 
    * Results from the phase II / III trial for the treatment of 
leg ulcers (venous leg ulcer, ulcerated leg) confirmed for the 
first time a clinical efficacy of DermaPro in this indication 
    * In treatment of leg ulcers with DermaPro a complete wound 
closure was achieved in 50% of treated patients 
    * Wound size in leg ulcer decreased by 62% compared to 
initial level with DermaPro treatment  
 
Source text for Eikon:  ID:nEQ8Hpmkfa  
Further company coverage:  T5OG.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;))

Recent news on bioXXmed AG

See all news